Trial reportPloS one2013
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.Antimicrobial agents and chemotherapy · 2018Trial
- Trial
- In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea.British journal of clinical pharmacology · 2025Article
- A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient.BMJ case reports · 2023Article
- Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review.Frontiers in endocrinology · 2022Review
- Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.The Journal of infection · 2019Article
- Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.The Journal of infectious diseases · 2019Article
- Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Observational
- Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.The Korean journal of internal medicine · 2019Article
- Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.The pharmacogenomics journal · 2018Article
- Categorization and association analysis of risk factors for adverse drug events.European journal of clinical pharmacology · 2018Review
- Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.European journal of drug metabolism and pharmacokinetics · 2017Review
- Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.The Journal of antimicrobial chemotherapy · 2017Article
- Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens.AIDS (London, England) · 2016Article
- Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.AIDS (London, England) · 2016Article
- Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?PloS one · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight<50 kg had significantly higher plasma tenofovir concentrations than those weighting >50 Kg (160±93 vs.71±52 ng/mL, p<0.001). High tenofovir plasma trough concentrations and the age of the patients were independently associated with the development of drug-related kidney and bone toxicity. In this retrospective study we have shown that HIV-infected women with low body weight are at risk to be exposed to high tenofovir plasma trough concentrations, ultimately resulting in a significant hazard to develop long-term tenofovir complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.